Drosera (drosera) is a bovine growth hormone and is an injectable form of progesterone. Drosera is the progestin type drug, which is not approved for use in men. Drosera is the trade name of desogestrel, a prescription ointment intended for oral use. Drosera is not recommended as a menstrual enhancer because its action has not been proved in animals. It was primarily intended to be an anabolic steroids replacement therapy for women undergoing mastectomy.
Drosera contains a metabolite of testosterone and has the effect of increasing free testosterone, as well as the production of estrogen. Drosera is a synthetic, rather than bioactive estradiol, which means it is not made naturally by the body, like estrogen and progesterone. In fact, the term ‘drufaxemia’ refers to a condition where the thyroid is abnormally slow in responding to the onset of estrogen and/or progesterone with the consequent release ofrogestive steroids.
Drosera causes estrogenic effects in several ways. Because theophylline, a component of the original chemical, has a weak Nolvadex estrogenic action, the introduction of theophylline produces estrogenic effects in humans, even when the dose is high. Theophylline can be metabolized in the liver and excreted, although some studies indicate that the release is too low and the body adapts by retaining some of the released estrogen. Another similarity with estrogenic effects is that, although theophylline is excreted, the levels are not reduced to the same degree as those seen with synthetic steroids and estrogen.
In animals, both the anti-estrogen effects of masteron and the estrogenic effects of the amino acid are restricted to the testes. But in humans, there is sufficient evidence that theophylline is also able to act on the mammary gland and may stimulate the secretion of estrogen there. Some evidence suggests that the compound is able to stimulate the production of human growth hormone (HGH), a component that is important in maintaining a stable and strong metabolism and whose absence is linked to a variety of age-related illnesses, including osteoporosis, cataract, kidney failure, and some types of cancer. A recent study indicated that a large proportion of HGH in the blood of healthy men and women could be due to the supplementation with masteron.
Like the well-known estrogen drug, clomiphene citrate, masteron has a half-life of about two hours. Its effect on cell growth is not particularly profound, although this can probably be expected because the concentration required to produce an effect is so small. Subsequently, metabolism of theophylline and its metabolite, ataraxyclic trinitrohormone (ATCT), is probably not affected by supplementation with masteron, although the amount of ATCT needed in these experiments was smaller. However, the anti-androgenic effect of masteron appears to be independent of its ability to stimulate the secretion of estrogen, since no relation was found between the concentration of ATCT and its effectiveness in enhancing libido or in counterbalancing the effect of androgens on the prostate and testicles. As regards hormonally, there is no sign of any feminization of the treated animals.
Like the estrogen drug clomiphene citrate, masteron has an anti-androgenic property. But unlike the estrogen drug, there are no indications that the anti-androgenic property is related to the ability of the compound to stimulate the secretion of estrogen. No studies have shown that the compound has any effect on breast cancer, although the data obtained concerning the use of low body fat concentration in the animals in the present study supports a conclusion that the combination of masteron and low body fat could have some effect on the risk of prostate cancer. The concentration of masteron in the plasma of the animals in this study was quite low, as it was determined by a process of blood analysis. This observation is confirmed by other studies.
The anabolic steroids hydroxymetabolism (muscle contraction) and metabolism have been studied intensively for more than forty years. Only recently have researchers focused their attention on the possible anti-androgenic properties of the amino acid. In fact, the search for an anti-androgenic substance began when the compound was isolated from a naturally occurring substance. Subsequently, the compound has received a great deal of attention. Because of the anabolic and catabolic effects of hydroxymetabolism and metabolism, the compound was discovered to be useful in treating various diseases associated with these processes.
The present investigation confirms that the anabolic and catabolic effects of masteron are mediated via its ability to act on the muscle protein receptor coupled with its ability to induce the intracellular and microcircular dynamics required for muscle protein accumulation and maintenance. It is believed that the intracellular signaling can be affected by decreasing the rate of muscle wasting and increasing the duration of muscle wasting. Finally, the molecular mechanism by which masteron affects the levels of estrogen and progesterone was revealed. Estrogen levels are decreased during periods of muscle wasting, which may explain why women undergoing weight training programs typically lose weight.